SCHEMBL2473674

SCHEMBL2473674

COc1ccc(C(=O)NC2CC2)cc1OC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.65
KMT2A Q03164 2/20 0.65
ALPL P05186 1/20 0.65
CYP2C9 P11712 2/20 0.61
CYP1A2 P05177 1/20 0.61
CYP3A4 P08684 1/20 0.61
TSHR P16473 1/20 0.61
CYP2C19 P33261 1/20 0.61
PDE4A P27815 1/20 0.60
PDE4B Q07343 1/20 0.60
PDE4C Q08493 1/20 0.60
PDE4D Q08499 1/20 0.60
CYP2D6 P10635 1/20 0.59
CA12 O43570 1/20 0.59
CA1 P00915 1/20 0.59
CA2 P00918 1/20 0.59
CA4 P22748 1/20 0.59
CA6 P23280 1/20 0.59
CA7 P43166 1/20 0.59
TPMT P51580 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9639296 0.98 MEN1 (0.64) MEN1KMT2AALPLCYP2C9CYP1A2
SCHEMBL3143526 0.94 KMT2A (0.74) MEN1KMT2AALPLCYP2C9CYP1A2
Hydrochloric Acid SCHEMBL9639562 0.94 KMT2A (0.70) MEN1KMT2AALPLCYP2C9PDE4A
SCHEMBL11687058 0.94 KMT2A (0.74) MEN1KMT2AALPLCYP2C9CYP1A2
Hydrochloric Acid SCHEMBL9639435 0.92 KMT2A (0.72) MEN1KMT2AALPLCYP2C9CYP1A2
SCHEMBL17758514 0.88 MAPK14 (0.56) MEN1KMT2AALPLPDE4BPDE4D
SCHEMBL90498 0.86 CNR2 (0.61) MEN1KMT2AALPLCYP2C9PDE4A
SCHEMBL89015 0.86 CNR2 (0.55) MEN1KMT2AALPLCYP2C9PDE4A
SCHEMBL27706504 0.86 ALDH1A1 (0.64) MEN1KMT2AALPLMAPK14ALDH1A1
SCHEMBL2546256 0.86 MAPK14 (0.52) MEN1KMT2AALPLMAPK14ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501830-B1 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES ACTELION PHARMACEUTICALS LTD (CH) 2011-10-05 EP claimed
US-20090069320-A1 Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof GRUENENTHAL GMBH (DE) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069320-A1 Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof GRM1, GRIN1, GRM2 MEN1 4274/4885KMT2A 1642/4885ALPL 4739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.